Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Discover the hidden triggers of idiopathic pulmonary fibrosis (IPF) in your home. Learn to minimize risks from scents, cleaning products, allergens, GERD, and infections.

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

Vicore Pharma and Endeavor BioMedicines have shared new data from two mid-stage clinical trials of two therapies that show promise in treating patients living with idiopathic pulmonary fibrosis (IPF).

AI models suggest IPF is a dysregulation of aging, not just accelerated aging, with unique gene expression patterns. Key pathways in IPF and aging include TGF-β signaling, oxidative stress, ...

Please provide your email address to receive an email when new articles are posted on . Thirty-eight percent of patients with IPF and OSA died, whereas this rate was 46% in patients with IPF only.